Day: December 13, 2021

Dallas, Texas, Dec. 13, 2021 (GLOBE NEWSWIRE) — WaterPure International, Inc. (OTC Pink: WPUR) today announced the company will publish an overview presentation on its off grid electric vehicle charging solution program developed for Alternet Systems, Inc. (OTC Pink: ALYI) this Thursday, December 16, 2021. ALYI has already started deploying electric motorcycles and electric three-wheel vehicles in East Africa into the taxi and delivery markets as one component of ALYI’s overall EV Ecosystem solution. WPUR has recently refreshed its commitment to delivering water management technologies to the water utilities market and added electric technology innovations for the electric utilities market as an additional focus. WPUR recently announced completing the acquisition of a company operating in East Africa, East African Development...

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) — Alpha Star Acquisition Corporation, a Cayman Island exempt company (NASDAQ: ALSAU) announced today that it has priced its initial public offering of 10,000,000 units at $10.00 per unit. The Company’s units are expected to be listed on NASDAQ Stock Market LLC Global Market (“NASDAQ”) and trade under the ticker symbol “ALSAU” beginning Monday, December 13, 2021. Each unit consists of one ordinary share par value $0.0001 per share, one right to receive one seventh (1/7) of an ordinary share and one redeemable warrant to acquire one-half an ordinary share at an exercise price of $11.50 for each whole share. The underlying securities of the units are not trading separately at this time. Once the securities comprising the units begin separate trading, the shares, rights, and warrants are...

Oslo (Norway), 13 December 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the Independent Data Monitoring Committee (IDMC) has reviewed the safety data collected thus far in the RELEASE trial and recommends that the trial continues with up to two fimaChem treatments as stated in the protocol. The ongoing pivotal RELEASE trial with registration intent was initiated with a planned safety review for the first eight patients receiving two fimaChem treatments. In the previously completed Phase I study a total of five patients received two treatments and now with additional eight patients reviewed for safety after two treatments, the RELEASE trial seamlessly continues to enrol patients for up to two fimaChem treatments. Per Walday, CEO of PCI Biotech, said: “With this positive initial safety...

More Assays Are Pending MIRAMICHI, New Brunswick, Dec. 13, 2021 (GLOBE NEWSWIRE) — SLAM Exploration Ltd. (“SLAM” or the “Company” on TSXV: SXL) is pleased to announce assay results for the first 5 diamond drill recently completed on its wholly-owned Menneval gold project located in the mineral-rich province of New Brunswick, Canada. Vein No. 18 returned up to 162.50 g/t gold over 0.2 m in hole BG2111 and anomalous gold is widespread in all 5 holes. Selected drilling results are shown in the following table:Hole_ID Zone From_m Core Length_m Sample Gold_g/tBG2109 No 18 Vein 15.25 0.20 34254 10.00BG2111 No 18 Vein 17.15 0.20 34275 162.50BG2111 No 18 Vein 33.72 0.80 34277 0.49BG2112 No 18 Vein 26.28 0.20 34282 1.57BG2113 No 9 Vein 3.25 0.85 34289 0.26BG2113 No 9 Vein 8.30 1.20 34296 1.72BG2113 No 9 Vein 10.50 0.40 34298 0.46BG2113 No...

 ALLO-715 UNIVERSAL Trial is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety and Substantial Efficacy in Multiple MyelomaUpdated Data Demonstrate Responses Similar to Approved Autologous CAR T TherapyALLO-715 Was Well Tolerated with No Graft-vs-Host Disease and Manageable Safety 71% Overall Response Rate (ORR) with FCA Lymphodepletion46% Achieved a Very Good Partial Response or Better (VGPR+) Including 25% Complete Response or Stringent Complete Response (CR/sCR) 92% of Patients with VGPR+ Were Minimal Residual Disease (MRD) Negative Median Duration of Response was 8.3 monthsStudy Highlights the Ability to Initiate AlloCAR T Therapy within Five Days of Enrollment with No Bridging Therapy Company to Host a Conference Call and Webcast Today, Monday, December 13, at 1:30 p.m. PT/4:30 p.m. ETSOUTH SAN FRANCISCO, Calif.,...

– Global Phase 3 ENERGIZE and ENERGIZE-T Studies of Mitapivat in Transfusion-dependent and Non-transfusion-dependent α- and β-Thalassemia Initiated – – Agios to Host Investor Webcast on Dec. 14, 2021, at 7:30 a.m. ET – CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today reported data for the first time from the ongoing long-term extension period of the Phase 2 open-label study of mitapivat, a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase (PK) enzymes, in adults with non-transfusion dependent α- or β-thalassemia. Data from the study were featured in an oral presentation at the American Society of Hematology (ASH) Annual...

ALPHA Trials Demonstrate Potential for AlloCAR T™ Therapy to be a Safe and Durable Alternative to Autologous Cell Therapy in CAR T Naïve Patients AlloCAR T Therapy was Associated with Consistent and Manageable Safety with No DLTs or GvHD; Low Rates of Grade 3 ICANs and CRS  No Relapses Observed in Large B Cell Lymphoma (LBCL) CAR T Naïve Patients Across Trials Who Achieved a Complete Response (CR) at Six MonthsLongest Ongoing CRs with ALLO-501 at 18+ Months and ALLO-501A 15+ MonthsCompany Plans to Initiate a Phase 2 Pivotal Trial in Relapsed/Refractory LBCL Utilizing Consolidation 1 Dosing with Lower Cyclophosphamide Pending Discussion with FDARegimen was Well Tolerated with Low Rates of Adverse Events Yielded a 44% CR Rate in LBCL with Ongoing CRs at 9 Months Consolidation Produced an 88% Overall Response Rate and 75% CR Rate...

– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma – – Results presented at ASH underscore potential of farnesyl transferase inhibition to drive clinical benefit in cancer patients with high unmet need – SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced final results from a Phase 2 study of tipifarnib as a monotherapy in patients with relapsed or refractory T-cell lymphoma, including an overall response rate (ORR) of 56% and a median overall survival of 32.8 months in heavily pretreated patients with angioimmunoblastic T-cell lymphoma (AITL). The final results are...

FAYETTEVILLE, Ark., Dec. 13, 2021 (GLOBE NEWSWIRE) — Black Hills Corp. (NYSE: BKH) today announced that its Arkansas natural gas utility, Black Hills Energy Arkansas, Inc., doing business as Black Hills Energy, filed a rate review application with the Arkansas Public Service Commission requesting $21.6 million in new annual revenue. Black Hills Energy has invested over $220 million in safety, system integrity and reliability for more than 7,200 miles of natural gas pipeline infrastructure in Arkansas since its last general rate filing in late 2017. These critical investments were required to meet system growth in the rapidly growing communities in the state, to ensure the safe and reliable delivery of natural gas to all customers’ homes and businesses and to meet compliance requirements of state and federal regulations. The importance...

– Posters presented at the 63rd American Society of Hematology Annual Meeting – SAN DIEGO and SUZHOU, China, Dec. 13, 2021 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced preclinical data demonstrating the compelling differentiation of ADG153, an anti-CD47 monoclonal antibody (mAb), and ADG152, a CD20xCD3 bispecific T-cell engager (TCE). The data were presented in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition taking place December 11-14, 2021, which are available in the Publications section of the company’s website at www.adagene.com. “Our novel anti-CD47 antibody and CD20xCD3 bispecific TCE programs successfully...